Your browser is no longer supported. Please, upgrade your browser.
EXEL Exelixis, Inc. daily Stock Chart
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.90 Insider Own1.90% Shs Outstand228.74M Perf Week0.78%
Market Cap1.78B Forward P/E- EPS next Y-0.50 Insider Trans1.40% Shs Float203.27M Perf Month20.18%
Income-195.90M PEG- EPS next Q-0.27 Inst Own78.90% Short Float23.58% Perf Quarter95.00%
Sales43.20M P/S41.30 EPS this Y41.30% Inst Trans1.71% Short Ratio9.04 Perf Half Y36.60%
Book/sh-0.68 P/B- EPS next Y39.80% ROA-54.50% Target Price7.67 Perf Year107.45%
Cash/sh1.41 P/C5.54 EPS next 5Y- ROE149.90% 52W Range3.31 - 7.88 Perf YTD38.30%
Dividend- P/FCF31.14 EPS past 5Y0.90% ROI-43.80% 52W High-1.02% Beta2.01
Dividend %- Quick Ratio3.30 Sales past 5Y-27.50% Gross Margin91.20% 52W Low135.65% ATR0.30
Employees115 Current Ratio3.40 Sales Q/Q63.80% Oper. Margin- RSI (14)69.75 Volatility4.66% 4.11%
OptionableYes Debt/Eq- EPS Q/Q-49.70% Profit Margin- Rel Volume1.18 Prev Close7.78
ShortableYes LT Debt/Eq- EarningsAug 04 AMC Payout- Avg Volume5.30M Price7.80
Recom1.60 SMA205.86% SMA5029.38% SMA20048.79% Volume6,249,915 Change0.26%
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Aug-14-08Initiated Banc of America Sec Neutral $7
Aug-06-08Reiterated Lazard Capital Buy $12 → $10
Jun-29-16 09:30AM featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
Jun-28-16 03:27PM  Explosive Stocks Under $10
Jun-23-16 11:30AM  Biotech Stock Bounce Picks Up Momentum at Forbes
Jun-15-16 08:03AM  4 Cancer Drug Developers You Need to Have on Your Radar This Year at Motley Fool
06:00AM  'Mad Money' Lightning Round: I'm Sticking With Wells Fargo
Jun-08-16 03:45PM  Exelixis, Inc. Setting New Standard of Care at Motley Fool
09:02AM  Research Coverage Scans Stocks on the Biotechnology Industry for Today
Jun-07-16 03:46PM  Exelixis Up on Positive Kidney Cancer Data on Cabometyx
08:15AM  Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Jun-06-16 05:08PM  Why Transocean, Exelixis, and CF Industries Jumped Today at Motley Fool +11.23%
04:18PM  Exelixis, Inc. Gets Some ASCO Love at Motley Fool
11:21AM  Heres Why These Five Stocks Are Surging Today at Insider Monkey
09:23AM  Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment
07:47AM  Exelixis's stock surges after positive results from trial of kidney cancer treatment at MarketWatch
07:30AM  Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting Business Wire
Jun-05-16 07:30PM  Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of Clinical Oncology Annual Meeting scheduled for 7:30 pm ET today
07:35AM  Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Business Wire
07:30AM  Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting Business Wire
Jun-03-16 10:03AM  Exelixis, Inc. Rides Cabometyx's Coattails to Big Gains in May at Motley Fool
May-31-16 03:04PM  These 2 Billionaires Are Dumping Exelixis' Stock. Should You? at Motley Fool
May-27-16 03:31PM  This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales at Motley Fool
May-26-16 04:14PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu
May-24-16 05:15PM  Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
May-23-16 09:02AM  Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Business Wire +7.91%
May-16-16 10:26AM  XBI and IHI Rose despite the Biotechnology Sectors Sluggish Week
08:45AM  Exelixis (EXEL) Worth a Look: Stock Up 8.1% in Session
May-12-16 04:50PM  Exelixis, Inc. Prepares for Blastoff at Motley Fool +6.13%
01:04PM  EXELIXIS, INC. Financials
May-11-16 07:40PM  ETFs with exposure to Exelixis, Inc. : May 11, 2016
May-09-16 12:01PM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q1, 2016 By the Numbers
May-05-16 04:05PM  Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10 Business Wire +8.31%
03:25PM  Exelixis (EXEL) Reports Wider-than-Expected Loss in Q1
07:35AM  3 Big Pharma Stocks With Credible Threats to Their Blockbusters at 24/7 Wall St.
01:19AM  Edited Transcript of EXEL earnings conference call or presentation 4-May-16 9:00pm GMT Thomson Reuters StreetEvents
May-04-16 05:13PM  Exelixis reports 1Q loss AP -7.28%
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:10PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
04:05PM  Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update Business Wire
12:01PM  2 Big Reasons Why Shares of Exelixis, Inc. Soared 15% in April at Motley Fool
07:07AM  Q1 2016 Exelixis Inc Earnings Release - After Market Close CCBN
May-03-16 09:50AM  Drug Stocks Reporting Mid-Week: MRK, ABC, ENDP & More Zacks
May-02-16 10:22AM  Exelixis (EXEL): What's Ahead for the Stock in Q1 Earnings? Zacks
Apr-27-16 03:48PM  Better Buy: Exelixis, Inc. vs. Roche at Motley Fool
Apr-26-16 04:05PM  Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016 Business Wire
03:00PM  Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin! at Motley Fool
12:19PM  Pay Attention to These 5 Stocks Making Big Moves Today at Insider Monkey
Apr-25-16 04:15PM  Peninsula drug developer scores comeback win for cancer-fighting tablet at American City Business Journals +5.67%
04:04PM  ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Business Wire
04:00PM  Exelixis, Inc. Conference Call to Discuss U.S. FDA Approval of CABOMETYX Tablets scheduled for 4:00 pm ET today CCBN
02:52PM  Exelixis Gets FDA Approval For Its CABOMETYX Tablets Benzinga
Apr-22-16 01:09PM  Why Are These Stocks Trading Deep in Red on Friday? at Insider Monkey
Apr-20-16 12:06PM  Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting Business Wire
Apr-07-16 10:43AM  Ignore Exelixis, Inc.: Here Are 3 Better Stocks at Motley Fool
Apr-05-16 08:06AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : April 5, 2016
Apr-04-16 11:43AM  Exelixis (EXEL) Stock Climbs, Stifel Upgrades at TheStreet +5.19%
07:42AM  Exelixis upgraded by Stifel
Mar-22-16 09:00AM  Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX Accesswire +5.96%
Mar-15-16 05:41PM  Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot at Motley Fool -10.43%
08:03AM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
Mar-09-16 10:30AM  Why Exelixis' Stock Dropped 10% on Tuesday at Motley Fool
Mar-07-16 03:02PM  Exelixis, Inc. Partnering Before Approval at Motley Fool +5.11%
Mar-06-16 11:03AM  Exelixis Inc. Stock Was Throttled in February -- Here's Why at Motley Fool
Mar-05-16 09:46AM  3 Healthcare Stocks Short-Sellers Are Wrong About at Motley Fool
Mar-03-16 04:05PM  Exelixis to Present at Two Investor Conferences in March Business Wire
Mar-02-16 12:02PM  Exelixis, Inc. Earnings Analysis: Q4, 2015 By the Numbers
08:00AM  Exelixis (EXEL) Shows Strength: Stock Moves 5.2% Higher
Mar-01-16 03:50PM  Why These 5 Stocks Are Making Moves Higher Today at Insider Monkey +5.22%
01:23PM  Exelixis (EXEL) Stock Climbs on Q4 Results at TheStreet
10:20AM  Exelixis Loss Narrower than Expected, Cabozantinib in Focus
01:22AM  Edited Transcript of EXEL earnings conference call or presentation 29-Feb-16 10:00pm GMT
Feb-29-16 06:01PM  7 Stocks Moving In Today's After-Hours Session -5.45%
05:42PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:55PM  Exelixis reports 4Q loss
04:08PM  Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update Business Wire
04:01PM  Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan Business Wire
07:07AM  Q4 2015 Exelixis Inc Earnings Release - After Market Close
Feb-25-16 02:15PM  What's in Store for Exelixis (EXEL) this Earnings Season?
Feb-16-16 05:20PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-15-16 08:30AM  Exelixis to Release Fourth Quarter and Full Year 2015 Financial Results on Monday, February 29, 2016 Business Wire
Feb-04-16 04:05PM  Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10 Business Wire +7.22%
Feb-03-16 02:44PM  Forget Gilead Sciences: These Stocks Doubled Last Year at Motley Fool
Feb-02-16 04:50PM  Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study
04:17PM  Emotional Investing Deflates Exelixis, Inc. in January at Motley Fool
Feb-01-16 09:05AM  Exelixis Rises on Positive Late-Stage Trial Results at 24/7 Wall St.
08:20AM  Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma at noodls
08:02AM  Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question at TheStreet
08:00AM  Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Business Wire
Jan-29-16 07:48PM  Why Exelixis, Inc. Rocketed Higher on Friday at Motley Fool +10.53%
04:20PM  Exelixis's Cabozantinib Granted Priority Review in the U.S.
Jan-28-16 04:05PM  Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma Business Wire
08:00AM  Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma Business Wire
Jan-27-16 08:00AM  Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Accesswire -7.53%
Jan-20-16 06:00AM  [video]'Mad Money' Lightning Round: Move on From Broadcom at TheStreet +8.43%
Jan-15-16 11:56AM  Bristol-Myers Squibb: A New Chapter, and the Beginning of Sustained Growth at Motley Fool -5.58%
Jan-12-16 08:00AM  Best Small-Cap Stocks of 2015 at Motley Fool
Jan-11-16 08:30AM  Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma Business Wire -5.11%
Jan-10-16 08:18AM  1 George Soros Quote to Keep in Mind in 2016 at Motley Fool
Jan-08-16 09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
Jan-07-16 04:20PM  Why #JPM16 matters: Biotechs open news spigots ahead of big conference at -6.81%
Exelixis, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for the treatment of cancer in the United States and the European Union. The company offers cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive and metastatic medullary thyroid cancer under the COMETRIQ brand name. It also focuses on developing cabozantinib as a treatment for patients with advanced renal cell carcinoma; and engages in a development program to explore the clinical potential of cabozantinib in additional tumor types, including a phase 3 trial of cabozantinib in advanced hepatocellular carcinoma. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM
WILLSEY LANCEDirectorDec 11Buy4.7850,000239,000494,975Dec 11 07:43 PM
WILLSEY LANCEDirectorDec 10Buy4.9950,000249,550444,975Dec 11 07:43 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Option Exercise5.6351,549290,22188,022Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Sale5.8051,549298,98436,473Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Option Exercise5.636003,37837,073Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Sale5.806003,48036,473Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Option Exercise5.63300,2761,690,554336,749Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Sale5.84300,2761,753,31236,473Oct 14 05:05 PM